DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Jonathan L. Prenner, MD
Retina Vitreous Center
Robert Wood Johnson Medical School of the University of Medicine and Dentistry
New Brunswick, NJ
K. Bailey Freund, MD
Vitreous- Retina-Macula Consultants of New York
New York University School of Medicine
New York Presbyterian Hospital
Manhattan Eye Ear & Throat Institute
Lenox Hill Hospital
New York, NY
Richard S. Kaiser, MD
Thomas Jefferson University
Wills Eye Hospital
Philadelphia, PA
Elias Reichel, MD
New England Eye Center
Tufts University School of Medicine
Boston, MA
FACULTY/STAFF DISCLOSURES
Jonathan L. Prenner, MD, has had a financial agreement or affiliation during the past year with the following: Genentech; Ophthotech Corporation; Neurotech, LLC; PanOptic; Regeneron Pharmaceuticals; and ThromboGenics.
K. Bailey Freund, MD, has had a financial agreement or affiliation during the past year with Alimera Sciences; Genentech; Heidleberg Engineering; Ohr Pharmaceutical; ThromboGenics; Optos; and Optovue.
Richard S. Kaiser, MD, has had a financial agreement or affiliation during the past year with Ophthotech Corporation; PanOptica; and Regeneron Pharmaceuticals.
Elias Reichel, MD, has had a financial agreement or affiliation during the past year with Genentech; Regeneron Pharmaceuticals; and ThromboGenics.
All of those involved in the planning, editing, and peer review of this educational activity report no relevant financial relationships.
DISCLOSURE POLICY
In accordance with the disclosure policies of The Dulaney Foundation and to conform with ACCME and US Food and Drug Administration guidelines, anyone in a position to affect the content of a CME activity is required to disclose to the activity participants (1) the existence of any financial interest or other relationships with the manufacturers of any commercial products/devices or providers of commercial services, and (2) identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
